What are the latest funding news in the AI in drug discovery market? (June 2026)
Download our beautiful pitch about the AI in drug discovery market
In our AI in drug discovery market deck, you will find everything you need to understand the market
AI drug discovery funding remained active in early 2026, with fresh capital going into platforms that design molecules, assess biologics, predict toxicity, and improve preclinical candidate selection.
The latest 12 qualifying rounds between February and May 2026 show a market that includes both very large AI drug design engines and smaller specialist tools for target discovery, protein characterization, and ADMET prediction.
The biggest signal came from Isomorphic Labs, but seed and Series A activity also showed that investors are still funding focused AI-native discovery workflows.
And if you want to better understand this new industry, you can download our pitch covering the AI in drug discovery market.
Insights
- Isomorphic Labs alone represented about 84% of the disclosed capital in this list, showing how much AI drug discovery funding can be concentrated in a few platform-scale companies.
- Seed rounds made up half of the latest 12 deals, which suggests the AI in drug discovery market is still producing many new specialist platforms.
- European companies were highly visible, with Helical, Generare, Ternary Therapeutics, Antiverse, and Pharmacelera all raising capital during the period.
- The market is moving beyond broad AI drug design engines, with funding also going to AI toxicology, protein characterization, drug delivery design, and molecular-glue discovery.
- Most disclosed valuations were unavailable, which is common in early AI biotech rounds but makes round size and investor quality more useful signals.
- Several companies raised for lab-in-the-loop validation, showing that investors still want AI discovery platforms to prove biology and chemistry, not just software performance.
- Biologics and antibody discovery appeared several times, with 10x Science and Antiverse showing demand for AI tools that help select better protein and antibody candidates.
- Preclinical prediction is becoming a clearer funding category, with DeepCyte focused on toxicity and 10x Science focused on candidate quality before clinical testing.
As this chart shows, and as featured in our AI in drug discovery market deck, search interest in AI drug discovery has grown rapidly
Summary table of the latest funding deals in the AI in drug discovery market as of June 2026
We define the AI in drug discovery market as revenue from AI-enabled software and related services that materially support the identification and design of therapeutic candidates before human trials.
We include AI used for target identification and validation, hit and lead generation, lead optimization, de novo design, repurposing, and preclinical prediction or assessment, including ADMET and toxicology.
We exclude AI primarily used for clinical trial operations, regulatory submissions, manufacturing, pharmacovigilance, or commercial and enterprise analytics not directly tied to discovery and preclinical candidate selection.
You can also read our detailed analysis to understand how funding activity in the AI in drug discovery market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the AI in drug discovery market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| METiS TechBio | 13 May 2026 | ~$270M | IPO | AI drug delivery, formulation & nanomaterial design |
| Isomorphic Labs | 12 May 2026 | $2,100M | Series B | AI drug design engine, de novo design & lead optimization |
| Fathom Therapeutics | 27 Apr 2026 | $47M | Series A | AI and quantum chemistry small-molecule design |
| 10x Science | 22 Apr 2026 | $4.8M | Seed | AI protein characterization & biologics candidate assessment |
| Helical | 14 Apr 2026 | $10M | Seed | Virtual AI lab for in-silico discovery workflows |
| DeepCyte | 9 Apr 2026 | $1.5M | Seed | Single-cell AI toxicology & ADMET prediction |
| Generare | 2 Apr 2026 | ~$23M | Series A | AI microbial-genome mining for novel molecule discovery |
| RyboDyn | 24 Mar 2026 | $10M | Seed initial close | AI target discovery & dark proteome mapping |
| Ternary Therapeutics | 16 Mar 2026 | ~$4.5M | Seed | AI molecular-glue design & targeted protein degradation |
| Antiverse | 3 Mar 2026 | $9.3M | Series A | AI antibody design for difficult disease targets |
| Tamarind Bio | 26 Feb 2026 | $13.6M | Series A plus additional funding | Molecular AI model infrastructure & simulation |
| Pharmacelera | 18 Feb 2026 | ~$6.5M | Venture round | Quantum and AI hit generation & lead optimization |
All the latest funding deals during in the AI in drug discovery market as of June 2026
METiS TechBio raised about $270M in its May 2026 IPO.
When was it?
The IPO was announced and listed on 13 May 2026.
Who are they?
METiS TechBio applies AI, molecular simulation, quantum chemistry, and high-throughput screening to design drug delivery and formulation systems.
Geographical focus?
METiS TechBio has a China and Hong Kong focus, with R&D links in Beijing, Hangzhou, Hong Kong, and Cambridge, Massachusetts.
Why do we include them in the AI in drug discovery market?
METiS TechBio belongs in this market because its AI platforms support drug delivery, formulation design, and preclinical candidate-enabling technology.
What is the company stage?
METiS TechBio is public and growth-stage, with clinical-stage candidates and platform infrastructure moving toward commercialization.
How much did they raise?
METiS TechBio raised about $270M in the IPO, or more than HK$2.1B.
What round is it?
The financing was an IPO on the Hong Kong Stock Exchange.
Why did they raise?
METiS TechBio raised to expand AI infrastructure, scale nanomaterial platforms, and fund ongoing and planned clinical work.
Isomorphic Labs raised $2.1B in a May 2026 Series B.
When was it?
The Series B was announced on 12 May 2026.
Who are they?
Isomorphic Labs is a Google DeepMind spinout building an AI-first drug design engine for small molecules, biologics, and antibody candidates.
Geographical focus?
Isomorphic Labs is headquartered in London and works globally, with sites and partnerships across major biopharma markets.
Why do we include them in the AI in drug discovery market?
Isomorphic Labs belongs in this market because its IsoDDE engine is built for AI drug design, de novo design, and lead optimization before trials.
What is the company stage?
Isomorphic Labs is growth-stage and appears to be moving from preclinical discovery toward clinical translation.
How much did they raise?
Isomorphic Labs raised $2,100M in this round.
What round is it?
The financing was a Series B round led by Thrive Capital.
Why did they raise?
Isomorphic Labs raised to scale IsoDDE, expand AI and drug-design teams, and advance internal and partnered programs.
This chart, featured in our AI in drug discovery market deck, compares the main business model options for AI drug discovery biotech companies
Fathom Therapeutics raised $47M in an April 2026 Series A.
When was it?
The Series A was announced on 27 April 2026.
Who are they?
Fathom Therapeutics, formerly Atommap, uses quantum chemistry and AI to predict how drug molecules behave inside living cells.
Geographical focus?
Fathom Therapeutics is based in New York and has a second office in Boston.
Why do we include them in the AI in drug discovery market?
Fathom Therapeutics belongs in this market because its platform directly supports AI-enabled small-molecule design and lead optimization.
What is the company stage?
Fathom Therapeutics is an early growth and preclinical platform-stage company.
How much did they raise?
Fathom Therapeutics raised $47M in this round.
What round is it?
The financing was an oversubscribed Series A round led by Sutter Hill Ventures.
Why did they raise?
Fathom Therapeutics raised to scale its computational drug-design platform, expand lab-in-the-loop validation, and advance internal programs.
10x Science raised $4.8M in an April 2026 Seed round.
When was it?
The Seed round was announced on 22 April 2026.
Who are they?
10x Science builds AI-native software for molecular-level protein characterization and biologics candidate assessment.
Geographical focus?
10x Science is based in the San Francisco Bay Area and targets global biopharma teams.
Why do we include them in the AI in drug discovery market?
10x Science belongs in this market because its platform helps drug developers decide which protein therapeutics should advance before human trials.
What is the company stage?
10x Science is at the MVP and early product-market-fit stage, with roots in Stanford-linked research and Y Combinator W26.
How much did they raise?
10x Science raised $4.8M in this round.
What round is it?
The financing was a Seed round led by Initialized Capital.
Why did they raise?
10x Science raised to build the foundational AI layer for protein characterization and support pharma and biotech adoption.
This chart, featured in our AI in drug discovery market deck, shows how Shrödinger is positioned in AI drug discovery
Helical raised $10M in an April 2026 Seed round.
When was it?
The Seed round was announced on 14 April 2026.
Who are they?
Helical builds a virtual AI lab that turns biological foundation models into reproducible in-silico drug discovery workflows.
Geographical focus?
Helical is UK and Europe-based and serves global pharmaceutical customers, including top-20 pharma companies.
Why do we include them in the AI in drug discovery market?
Helical belongs in this market because its AI foundation-model infrastructure supports target discovery, biomarker discovery, and therapeutic design workflows.
What is the company stage?
Helical is at the early product-market-fit stage, with visible pharma customer traction.
How much did they raise?
Helical raised $10M in this round.
What round is it?
The financing was a Seed round led by redalpine.
Why did they raise?
Helical raised to scale its virtual lab, expand pharma programs, and make in-silico discovery reproducible at pharma scale.
DeepCyte raised $1.5M in an April 2026 Seed round.
When was it?
The Seed round was announced on 9 April 2026.
Who are they?
DeepCyte develops single-cell AI toxicology tools that detect, predict, and explain drug-induced toxicity before drugs reach patients.
Geographical focus?
DeepCyte has a US-Danish footprint and targets biopharma customers globally.
Why do we include them in the AI in drug discovery market?
DeepCyte belongs in this market because its platform supports preclinical ADMET and toxicity prediction for candidate de-risking.
What is the company stage?
DeepCyte is at launch and MVP stage, with products called MetaCore and DeeImmuno.
How much did they raise?
DeepCyte raised $1.5M in this round.
What round is it?
The financing was a Seed round with the full syndicate not fully disclosed in accessible sources.
Why did they raise?
DeepCyte raised to launch and advance its single-cell AI toxicology platform.
In our AI in drug discovery market deck, we identify pain points entrepreneurs should prioritize
Generare raised about $23M in an April 2026 Series A.
When was it?
The Series A was announced on 2 April 2026.
Who are they?
Generare uses AI to decode microbial genomes and generate novel molecular data for discovering new drug-like compounds.
Geographical focus?
Generare is based in Paris and focuses on global drug-development customers.
Why do we include them in the AI in drug discovery market?
Generare belongs in this market because its AI-enabled genomic mining platform supports hit generation and novel molecule discovery.
What is the company stage?
Generare is an early growth and platform-stage company scaling a proprietary discovery library.
How much did they raise?
Generare raised €20M, equal to about $23M.
What round is it?
The financing was a Series A round co-led by Alven and Daphni.
Why did they raise?
Generare raised to expand its compound library, grow the team, and scale the discovery platform.
RyboDyn raised $10M in a March 2026 Seed initial close.
When was it?
The Seed initial close was announced on 24 March 2026.
Who are they?
RyboDyn uses AI and high-resolution sequencing to decode the dark proteome and identify hidden cancer targets.
Geographical focus?
RyboDyn is based in San Diego and is focused on oncology target discovery with global relevance.
Why do we include them in the AI in drug discovery market?
RyboDyn belongs in this market because its platform supports AI target discovery and target validation before therapeutic development.
What is the company stage?
RyboDyn is moving from MVP and early platform scale toward IND-enabling work.
How much did they raise?
RyboDyn raised $10M in an initial Seed close.
What round is it?
The financing was a Seed initial close, with no single lead investor clearly disclosed.
Why did they raise?
RyboDyn raised to scale RyboCypher and CypherAtlas and progress early oncology programs toward IND-enabling studies.
This market map, featured in our AI in drug discovery market deck, highlights top companies and startups in the AI in drug discovery market
Ternary Therapeutics raised about $4.5M in a March 2026 Seed round.
When was it?
The Seed round was announced on 16 March 2026.
Who are they?
Ternary Therapeutics uses machine learning, molecular modeling, and lab feedback to design molecular-glue drugs.
Geographical focus?
Ternary Therapeutics is based in London, with lab space at Stevenage Bioscience Catalyst.
Why do we include them in the AI in drug discovery market?
Ternary Therapeutics belongs in this market because its AI platform designs molecular-glue therapeutic candidates before trials.
What is the company stage?
Ternary Therapeutics is a preclinical platform and MVP-stage company.
How much did they raise?
Ternary Therapeutics raised €4.1M, equal to about $4.5M.
What round is it?
The financing was a Seed round led by Daphni.
Why did they raise?
Ternary Therapeutics raised to scale its AI platform, expand biology and chemistry capabilities, and make molecular-glue discovery more systematic.
Antiverse raised $9.3M in a March 2026 Series A.
When was it?
The Series A was announced on 3 March 2026.
Who are they?
Antiverse designs therapeutic antibodies for difficult targets such as GPCRs and ion channels using AI and in-house lab validation.
Geographical focus?
Antiverse is headquartered in Cardiff, with offices in Boston and Prague.
Why do we include them in the AI in drug discovery market?
Antiverse belongs in this market because its platform supports AI antibody design and biologics lead generation before human trials.
What is the company stage?
Antiverse is at product-market-fit and preclinical program stage, with partner work and internal lead programs.
How much did they raise?
Antiverse raised $9.3M in this round.
What round is it?
The financing was a Series A round led by Soulmates Ventures.
Why did they raise?
Antiverse raised to accelerate internal antibody programs toward in-vivo efficacy studies and expand partner programs.
This chart, featured in our AI in drug discovery market deck, shows annual funding in AI drug discovery startups
Tamarind Bio raised $13.6M in February 2026 combined funding.
When was it?
The funding was announced on 26 February 2026.
Who are they?
Tamarind Bio provides no-code infrastructure for life-science teams to run molecular AI and simulation models.
Geographical focus?
Tamarind Bio is based in San Francisco and serves biotech and pharma users globally.
Why do we include them in the AI in drug discovery market?
Tamarind Bio belongs in this market because its platform enables molecular AI models for discovery workflows and preclinical decision-making.
What is the company stage?
Tamarind Bio is at product-market-fit and early growth stage, with adoption across roughly 100 biotech organizations.
How much did they raise?
Tamarind Bio raised $13.6M total, including a $12M Series A.
What round is it?
The financing was a Series A plus additional funding, led by Dimension Capital.
Why did they raise?
Tamarind Bio raised to build core infrastructure for AI-powered drug discovery inference and make molecular AI usable by bench scientists.
Pharmacelera raised about $6.5M in February 2026 venture funding.
When was it?
The venture funding round was announced on 18 February 2026.
Who are they?
Pharmacelera combines quantum mechanics and AI to find structurally diverse, synthesizable, drug-like compounds.
Geographical focus?
Pharmacelera is based in Barcelona and is expanding commercially in the United States while serving global pharma and biotech customers.
Why do we include them in the AI in drug discovery market?
Pharmacelera belongs in this market because its platform supports AI hit generation and lead optimization for early-stage molecule discovery.
What is the company stage?
Pharmacelera is a growth-stage company with a commercial discovery platform and more than 100 projects completed.
How much did they raise?
Pharmacelera raised €6M, equal to about $6.5M.
What round is it?
The financing was a venture funding round led by Heran Partners.
Why did they raise?
Pharmacelera raised to expand in the United States and improve its AI and quantum-mechanics drug discovery platform.
Related blog posts
- How strong is fundraising in the AI in drug discovery market right now?
- The latest news in AI for drug discovery
- How large is the AI in drug discovery market in reality?
- The evolution of funding activity in AI for drug discovery
- The main fundraising trends in AI for drug discovery
- All funding deals in AI for drug discovery
- Which companies have raised the most funding in AI for drug discovery?
- Which companies are the most valued in AI for drug discovery?
- A complete list of business models in AI for drug discovery
